Nuclear Receptors and Drug-Drug Interactions with Prescription and Herbal Medicines

Nuclear Receptors in Drug Metabolism

Volumn , Issue , 2008, Pages 211-239

  Tirona, Rommel G ^a   Kim, Richard B ^a  

^a WESTERN UNIVERSITY   (Canada)

Author keywords

Induction mediated drug interactions; Nuclear receptors and drug drug interactions with prescription; Pharmaceutical industry and pharmacology of induction

Indexed keywords

EID: 84890751175     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470409107.ch8     Document Type: Chapter

References (168)

1. Lazarou, J., Pomeranz, B. H., and Corey, P. N. (1998) Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279, 1200-1205.
2. Kohler, G. I., Bode-Boger, S. M., Busse, R., Hoopmann, M.,Welte, T., and Boger, R. H. (2000) Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. Int. J. Clin. Pharmacol. Ther. 38, 504-513.
3. Conney, A. H., Davison, C., Gastel, R., and Burns, J. J. (1960) Adaptive increases in drug-metabolizing enzymes induced by phenobarbital and other drugs. J. Pharmacol. Exp. Ther. 130, 1-8.
4. Cucinell, S. A., Koster, R., Conney, A. H., and Burns, J. J. (1963) Stimulatory effect of phenobarbital on the metabolism of diphenylhydantoin. J. Pharmacol. Exp. Ther. 141, 157-160.
5. Remmer, H., Schoene, B., and Fleischmann, R. A. (1973) Induction of the unspecific microsomal hydroxylase in the human liver. Drug Metab. Dispos. 1, 224-230.
6. Adesnik, M., Bar-Nun, S., Maschio, F., Zunich, M., Lippman, A., and Bard, E. (1981) Mechanism of induction of cytochrome P-450 by phenobarbital. J. Biol. Chem. 256, 10340-10345.
7. Kliewer, S. A., Moore, J. T., Wade, L., Staudinger, J. L., Watson, M. A., Jones, S. A., McKee, D. D., Oliver, B. B., Willson, T. M., Zetterstrom, R. H., et al. (1998) An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 92, 73-82.
8. Lehmann, J. M.,McKee, D. D.,Watson, M. A.,Willson, T. M.,Moore, J. T., and Kliewer, S. A. (1998) The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J. Clin. Invest. 102, 1016-1023.
9. Goodwin, B., Hodgson, E., and Liddle, C. (1999) The orphan human pregnane X receptor mediates the transcriptional activation ofCYP3A4 by rifampicin through a distal enhancer module. Mol. Pharmacol. 56, 1329-1339.
10. Bertilsson, G., Heidrich, J., Svensson, K., Asman, M., Jendeberg, L., Sydow-Backman, M., Ohlsson, R., Postlind, H., Blomquist, P., and Berkenstam, A. (1998) Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc. Natl Acad. Sci. USA 95, 12208-12213.
11. Blumberg, B., Sabbagh,W., Jr., Juguilon, H., Bolado, J., Jr., Van Meter, C. M., Ong, E. S., and Evans, R. M. (1998) SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev. 12, 3195-3205.
12. Forman, B. M., Tzameli, I., Choi, H. S., Chen, J., Simha, D., Seol,W., Evans, R. M., and Moore, D. D. (1998) Androstane metabolites bind to and deactivate the nuclear receptor CAR-beta. Nature 395, 612-615.
13. Sueyoshi, T., Kawamoto, T., Zelko, I., Honkakoski, P., and Negishi, M. (1999) The repressed nuclear receptorCARresponds to phenobarbital in activating the humanCYP2B6 gene. J. Biol. Chem. 274, 6043-6046.
14. Honkakoski, P., Zelko, I., Sueyoshi, T., and Negishi, M. (1998) The nuclear orphan receptor CAR-retinoid X receptor heterodimer activates the phenobarbital-responsive enhancer module of the CYP2B gene. Mol. Cell. Biol. 18, 5652-5658.
15. Baes, M., Gulick, T., Choi, H. S., Martinoli, M. G., Simha, D., and Moore, D. D. (1994) A new orphan member of the nuclear hormone receptor superfamily that interacts with a subset of retinoic acid response elements. Mol. Cell. Biol. 14, 1544-1551.
16. Goodwin, B., Moore, L. B., Stoltz, C.M., McKee, D. D., and Kliewer, S. A. (2001) Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor. Mol. Pharmacol. 60, 427-431.
17. Wang, H., Faucette, S., Sueyoshi, T., Moore, R., Ferguson, S., Negishi,M., and LeCluyse, E. L. (2003)Anovel distal enhancer module regulated by pregnaneXreceptor/constitutive androstane receptor is essential for the maximal induction of CYP2B6 gene expression. J. Biol. Chem. 278, 14146-14152.
18. Chen, Y., Ferguson, S. S., Negishi, M., and Goldstein, J. A. (2004) Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor. J. Pharmacol. Exp. Ther. 308, 495-501.
19. Gerbal-Chaloin, S., Daujat, M., Pascussi, J. M., Pichard-Garcia, L., Vilarem, M. J., and Maurel, P. (2002) Transcriptional regulation of CYP2C9 gene. Role of glucocorticoid receptor and constitutive androstane receptor. J. Biol. Chem. 277, 209-217.
20. Ferguson, S. S., LeCluyse, E. L., Negishi, M., and Goldstein, J. A. (2002) Regulation of human CYP2C9 by the constitutive androstane receptor: discovery of a new distal binding site. Mol. Pharmacol. 62, 737-746.
21. Chen, Y., Ferguson, S. S., Negishi, M., and Goldstein, J. A. (2003) Identification of constitutive androstane receptor and glucocorticoid receptor binding sites in the CYP2C19 promoter. Mol. Pharmacol. 64, 316-324.
22. Gerbal-Chaloin, S., Pascussi, J. M., Pichard-Garcia, L., Daujat, M., Waechter, F., Fabre, J. M., Carrere,N., andMaurel, P. (2001) Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab. Dispos. 29, 242-251.
23. Pascussi, J. M., Jounaidi, Y., Drocourt, L., Domergue, J., Balabaud, C., Maurel, P., and Vilarem, M. J. (1999) Evidence for the presence of a functional pregnane X receptor response element in the CYP3A7 promoter gene. Biochem. Biophys. Res. Commun. 260, 377-381.
24. Bertilsson, G., Berkenstam, A., and Blomquist, P. (2001) Functionally conserved xenobiotic responsive enhancer in cytochrome P450 3A7. Biochem. Biophys. Res. Commun. 280, 139-144.
25. Sugatani, J., Kojima, H., Ueda, A., Kakizaki, S., Yoshinari, K., Gong, Q. H., Owens, I. S., Negishi, M., and Sueyoshi, T. (2001) The phenobarbital response enhancer module in the human bilirubin UDP-glucuronosyltransferase UGT1A1 gene and regulation by the nuclear receptor CAR. Hepatology 33, 1232-1238.
26. Sugatani, J., Yamakawa, K., Tonda, E., Nishitani, S., Yoshinari, K., Degawa, M., Abe, I., Noguchi,H., andMiwa, M. (2004) The induction of human UDP-glucuronosyltransferase 1A1 mediated through a distal enhancer module by flavonoids and xenobiotics. Biochem. Pharmacol. 67, 989-1000.
27. Gardner-Stephen, D., Heydel, J. M., Goyal, A., Lu, Y., Xie, W., Lindblom, T., Mackenzie, P., and Radominska-Pandya, A. (2004) Human PXR variants and their differential effects on the regulation of human UDP-glucuronosyltransferase gene expression. Drug Metab. Dispos. 32, 340-347.
28. Echchgadda, I., Song, C. S., Oh, T., Ahmed, M., De La Cruz, I. J., and Chatterjee, B. (2007) The xenobiotic-sensing nuclear receptors pregnane X receptor, constitutive androstane receptor, and orphan nuclear receptor hepatocyte nuclear factor 4{alpha} in the regulation of human steroid-/bile acid-sulfotransferase. Mol. Endocrinol. 21, 2099-2111.
29. Fang, H. L., Strom, S. C., Ellis, E., Duanmu, Z., Fu, J., Duniec-Dmuchowski, Z., Falany, C. N., Falany, J. L., Kocarek, T. A., and Runge-Morris, M. (2007) Positive and negative regulation of human hepatic hydroxysteroid sulfotransferase (SULT2A1) gene transcription by rifampicin: roles of hepatocyte nuclear factor 4{alpha} and pregnane X receptor. J. Pharmacol. Exp. Ther. 323, 586-598.
30. Geick, A., Eichelbaum, M., and Burk, O. (2001) Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J. Biol. Chem. 276, 14581-14587.
31. Kast, H. R., Goodwin, B., Tarr, P. T., Jones, S. A., Anisfeld, A. M., Stoltz, C. M., Tontonoz, P., Kliewer, S., Willson, T. M., and Edwards, P. A. (2002) Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J. Biol. Chem. 277, 2908-2915.
32. Assem, M., Schuetz, E. G., Leggas, M., Sun, D., Yasuda, K., Reid, G., Zelcer, N., Adachi, M., Strom, S., Evans, R. M., et al. (2004) Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice. J. Biol. Chem. 279, 22250-22257.
33. Miki,Y., Suzuki, T., Kitada,K.,Yabuki,N., Shibuya,R., Moriya, T., Ishida, T., Ohuchi,N., Blumberg, B., and Sasano, H. (2006) Expression of the steroid and xenobiotic receptor and its possible target gene, organic anion transporting polypeptide-A, in human breast carcinoma. Cancer Res. 66, 535-542.
34. Cucinell, S. A., Conney, A. H., Sansur, M., and Burns, J. J. (1965) Drug interactions in man. I. Lowering effect of phenobarbital on plasma levels of bishydroxycoumarin (dicumarol) and diphenylhydantoin (dilantin). Clin. Pharmacol. Ther. 6, 420-429.
35. Rawlins, M. D., Collste, P., Bertilsson, L., and Palmer, L. (1975) Distribution and elimination kinetics of carbamazepine in man. Eur. J. Clin. Pharmacol. 8, 91-96.
36. Moore, L. B., Parks, D. J., Jones, S. A., Bledsoe, R. K., Consler, T. G., Stimmel, J. B., Goodwin, B., Liddle, C., Blanchard, S. G., Willson, T. M., et al. (2000) Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. J. Biol. Chem. 275, 15122-15127.
37. Faucette, S. R., Zhang, T. C., Moore, R., Sueyoshi, T., Omiecinski, C. J., LeCluyse, E. L., Negishi, M., and Wang, H. (2007) Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J. Pharmacol. Exp. Ther. 320, 72-80.
38. Wang, H., Faucette, S., Moore, R., Sueyoshi, T., Negishi, M., and LeCluyse, E. (2004) Human constitutive androstane receptor mediates induction of CYP2B6 gene expression by phenytoin. J. Biol. Chem. 279, 29295-29301.
39. Nallani, S. C., Glauser, T. A., Hariparsad, N., Setchell, K., Buckley, D. J., Buckley, A. R., and Desai, P. B. (2003) Dose-dependent induction of cytochrome P450 (CYP) 3A4 and activation of pregnane X receptor by topiramate. Epilepsia 44, 1521- 1528.
40. Cerveny, L., Svecova, L., Anzenbacherova, E.,Vrzal, R., Staud, F.,Dvorak, Z.,Ulrichova, J., Anzenbacher, P., and Pavek, P. (2007) Valproic acid induces CYP3A4 andMDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways. Drug Metab. Dispos. 35, 1032-1041.
41. Michot, F., Burgi, M., and Buttner, J. (1970) Rimactan (rifampicin) and anticoagulant therapy. Schweiz. Med. Wochenschr. 100, 583-584.
42. Reimers, D. and Jezek, A. (1971) The simultaneous use of rifampicin and other antitubercular agents with oral contraceptives. Prax. Pneumol. 25, 255-262.
43. Finch, C. K., Chrisman, C. R., Baciewicz, A. M., and Self, T. H. (2002) Rifampin and rifabutin drug interactions: an update. Arch. Intern. Med. 162, 985-992.
44. Justesen, U. S., Klitgaard, N. A., Brosen, K., and Pedersen, C. (2003) Pharmacokinetic interaction between amprenavir and delavirdine after multiple-dose administration in healthy volunteers. Br. J. Clin. Pharmacol. 55, 100-106.
45. Hendrix, C. W., Wakeford, J., Wire, M. B., Lou, Y., Bigelow, G. E., Martinez, E., Christopher, J., Fuchs, E. J., and Snidow, J. W. (2004) Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with amprenavir in opioid-dependent subjects. Pharmacotherapy 24, 1110-1121.
46. Cantilena, L., McCrae, J., Blazes, D.,Winchell, G., Carides, A., Royce, C., and Deutsch, P. (1999) Lack of pharmacokinetic interaction between indinavir and methadone. Clin. Pharmacol. Ther. 65, 135.
47. McCance-Katz, E. F., Rainey, P. M., Friedland, G., and Jatlow, P. (2003) The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients. Clin. Infect. Dis. 37, 476-482.
48. Hsyu, P. H., Schultz-Smith,M. D., Lillibridge, J. H., Lewis, R. H., and Kerr, B. M. (2001) Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Antimicrob. Agents Chemother. 45, 3445-3450.
49. Hsyu, P. H., Lillibridge, J. H., Maroldo, L., Weiss, W. R., and Kerr, B. M. (2000) Pharmacokinetic (PK) and pharmacodynamic (PD) interactions between nelfinavir and methadone. 7th CROI, Abstract 87.
50. Hsu, A., Granneman, G. R., Carothers, L., Dennis, S., Chiu, L., Valdes, J., and Sun, E. (1998) Ritonavir does not increase methadone exposure in healthy volunteers. 5th CROI, Abstract 324.
51. Shelton, M. J., Cloen, D., DiFrancesco, R., Berenson, C. S., Esch, A., de Caprariis, P. J., Palic, B., Schur, J. L., Bugge, C. J., Ljungqvist, A., et al. (2004) The effects of once-daily saquinavir/minidose ritonavir on the pharmacokinetics of methadone. J. Clin. Pharmacol. 44, 293-304.
52. Clarke, S. M., Mulcahy, F. M., Tjia, J., Reynolds, H. E., Gibbons, S. E., Barry, M. G., and Back, D. J. (2001) The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. Br. J. Clin. Pharmacol. 51, 213-217.
53. Murphy, R. L., Sommadossi, J. P., Lamson, M., Hall, D. B., Myers, M., and Dusek, A. (1999) Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1. J. Infect. Dis. 179, 1116-1123.
54. Clarke, S. M., Mulcahy, F. M., Tjia, J., Reynolds, H. E., Gibbons, S. E., Barry, M. G., and Back, D. J. (2001) Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users. Clin. Infect. Dis. 33, 1595-1597.
55. Brown, L. S., Sawyer, R. C., Li, R., Cobb, M. N., Colborn, D. C., and Narang, P. K. (1996) Lack of a pharmacologic interaction between rifabutin and methadone in HIV-infected former injecting drug users. Drug Alcohol Depend. 43, 71-77.
56. Kreek, M. J., Garfield, J. W., Gutjahr, C. L., and Giusti, L. M. (1976) Rifampin-induced methadone withdrawal. N. Engl. J. Med. 294, 1104-1106.
57. Trapnell, C. B., Connolly, M., Pentikis, H., Forbes, W. P., and Bettenhausen, D. K. (2007) Absence of effect of oral rifaximin on the pharmacokinetics of ethinyl estradiol/ norgestimate in healthy females. Ann. Pharmacother. 41, 222-228.
58. Ma, X., Shah, Y. M., Guo, G. L.,Wang, T., Krausz, K.W., Idle, J. R., and Gonzalez, F. J. (2007) Rifaximin is a gut-specific human pregnane X receptor activator. J. Pharmacol. Exp. Ther. 322, 391-398.
59. Shah, Y. M., Ma, X., Morimura, K., Kim, I., and Gonzalez, F. J. (2007) Pregnane X receptor activation ameliorates DSS-induced inflammatory bowel disease via inhibition of NF-kappaB target gene expression. Am. J. Physiol. Gastrointest. Liver Physiol. 292, G1114-G1122.
60. Zhou, C., Tabb, M. M., Nelson, E. L., Grun, F., Verma, S., Sadatrafiei, A., Lin, M., Mallick, S., Forman, B. M., Thummel, K. E., et al. (2006) Mutual repression between steroid and xenobiotic receptor and NF-kappaB signaling pathways links xenobiotic metabolism and inflammation. J. Clin. Invest. 116, 2280-2289.
61. Ouellet, D., Hsu, A., Qian, J., Locke, C. S., Eason, C. J., Cavanaugh, J. H., Leonard, J. M., and Granneman, G. R. (1998) Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. Br. J. Clin. Pharmacol. 46, 111-116.
62. Dussault, I., Lin,M., Hollister, K.,Wang, E. H., Synold, T.W., and Forman, B.M. (2001) Peptide mimetic HIV protease inhibitors are ligands for the orphan receptor SXR. J. Biol. Chem. 276, 33309-33312.
63. Dixit, V., Hariparsad, N., Li, F., Desai, P., Thummel, K. E., and Unadkat, J. D. (2007) Cytochrome P450 enzymes and transporters induced by anti-HIV protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions. Drug Metab. Dispos. 35, 1853-1859.
64. Mukwaya, G., MacGregor, T., Hoelscher, D., Heming, T., Legg, D., Kavanaugh, K., Johnson, P., Sabo, J. P., and McCallister, S. (2005) Interaction of ritonavir-boosted tipranavir with loperamide does not result in loperamide-associated neurologic side effects in healthy volunteers. Antimicrob. Agents Chemother. 49, 4903-4910.
65. Koudriakova, T., Iatsimirskaia, E., Utkin, I., Gangl, E., Vouros, P., Storozhuk, E., Orza, D.,Marinina, J., and Gerber, N. (1998) Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metab. Dispos. 26, 552-561.
66. Heelon, M. W. and Meade, L. B. (1999) Methadone withdrawal when starting an antiretroviral regimen including nevirapine. Pharmacotherapy 19, 471-472.
67. Van Giersbergen, P. L., Halabi, A., and Dingemanse, J. (2002) Single- and multipledose pharmacokinetics of bosentan and its interaction with ketoconazole. Br. J. Clin. Pharmacol. 53, 589-595.
68. Van Giersbergen, P. L., Gnerre, C., Treiber, A., Dingemanse, J., and Meyer, U. A. (2002) Bosentan, a dual endothelin receptor antagonist, activates the pregnane X nuclear receptor. Eur. J. Pharmacol. 450, 115-121.
69. Kennedy, J. (2005) Herb and supplement use in the US adult population. Clin. Ther. 27, 1847-1858.
70. Peng, C. C., Glassman, P. A., Trilli, L. E., Hayes-Hunter, J., and Good, C. B. (2004) Incidence and severity of potential drug-dietary supplement interactions in primary care patients: an exploratory study of 2 outpatient practices. Arch. Intern. Med. 164, 630-636.
71. Sparreboom, A., Cox, M. C., Acharya,M. R., and Figg,W. D. (2004) Herbal remedies in the United States: potential adverse interactions with anticancer agents. J. Clin. Oncol. 22, 2489-2503.
72. Ruschitzka, F., Meier, P. J., Turina, M., Luscher, T. F., and Noll, G. (2000) Acute heart transplant rejection due to Saint John's wort. Lancet 355, 548-549.
73. Piscitelli, S. C., Burstein, A. H., Chaitt, D., Alfaro, R. M., and Falloon, J. (2000) Indinavir concentrations and St. John's wort. Lancet 355, 547-548.
74. Wang, L. S., Zhou, G., Zhu, B., Wu, J., Wang, J. G., Abd El-Aty, A. M., Li, T., Liu, J., Yang, T. L., Wang, D., et al. (2004) St. John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole. Clin. Pharmacol. Ther. 75, 191-197.
75. Johne, A., Brockmoller, J., Bauer, S., Maurer, A., Langheinrich,M., and Roots, I. (1999) Pharmacokinetic interaction of digoxin with an herbal extract from St. John's wort (Hypericum perforatum). Clin. Pharmacol. Ther. 66, 338-345.
76. Durr, D., Stieger, B., Kullak-Ublick, G. A., Rentsch, K. M., Steinert, H. C., Meier, P. J., and Fattinger, K. (2000) St. John's wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin. Pharmacol. Ther. 68, 598-604.
77. Frye, R. F., Fitzgerald, S. M., Lagattuta, T. F., Hruska, M. W., and Egorin, M. J. (2004) Effect of St. John's wort on imatinib mesylate pharmacokinetics. Clin. Pharmacol. Ther. 76, 323-329.
78. Schwarz, U. I.,Buschel,B., andKirch,W. (2003)Unwanted pregnancy on self-medication with St. John'swort despite hormonal contraception.Br. J. Clin. Pharmacol. 55, 112-113.
79. Mai, I., Stormer, E., Bauer, S., Kruger, H., Budde, K., and Roots, I. (2003) Impact of St. John's wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. Nephrol. Dial. Transplant. 18, 819-822.
80. Yue, Q. Y., Bergquist, C., and Gerden, B. (2000) Safety of St. John's wort (Hypericum perforatum). Lancet 355, 576-577.
81. Nebel, A., Schneider, B. J., Baker, R. K., and Kroll, D. J. (1999) Potential metabolic interaction between St. John's wort and theophylline. Ann. Pharmacother. 33, 502.
82. Dresser, G. K., Schwarz, U. I., Wilkinson, G. R., and Kim, R. B. (2003) Coordinate induction of both cytochrome P4503A and MDR1 by St. John's wort in healthy subjects. Clin. Pharmacol. Ther. 73, 41-50.
83. Markowitz, J. S., Donovan, J. L., DeVane, C. L., Taylor, R. M., Ruan, Y., Wang, J. S., and Chavin, K. D. (2003) Effect of St. John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 290 1500-1504.
84. Kawaguchi, A., Ohmori, M., Tsuruoka, S., Nishiki, K., Harada, K., Miyamori, I., Yano, R., Nakamura, T., Masada, M., and Fujimura, A. (2004) Drug interaction between St. John's wort and quazepam. Br. J. Clin. Pharmacol. 58, 403-410.
85. Schwarz, U. I., Hanso, H., Oertel, R., Miehlke, S., Kuhlisch, E., Glaeser, H., Hitzl, M., Dresser, G. K., Kim, R. B., and Kirch, W. (2007) Induction of intestinal P-glycoprotein by St. John's wort reduces the oral bioavailability of talinolol. Clin. Pharmacol. Ther. 81, 669-678.
86. Portoles, A., Terleira, A., Calvo, A., Martinez, I., and Resplandy, G. (2006) Effects of Hypericum perforatum on ivabradine pharmacokinetics in healthy volunteers: an openlabel, pharmacokinetic interaction clinical trial. J. Clin. Pharmacol. 46, 1188-1194.
87. Mathijssen, R. H., Verweij, J., de Bruijn, P., Loos, W. J., and Sparreboom, A. (2002) Effects of St. John's wort on irinotecan metabolism. J. Natl Cancer. Inst. 94, 1247-1249.
88. Gorski, J. C., Huang, S. M., Pinto, A., Hamman, M. A., Hilligoss, J. K., Zaheer, N. A., Desai,M., Miller, M., and Hall, S. D. (2004) The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin. Pharmacol. Ther. 75, 89-100.
89. Piscitelli, S. C., Burstein, A. H.,Welden, N., Gallicano, K. D., and Falloon, J. (2002) The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin. Infect. Dis. 34, 234-238.
90. Yin, O. Q., Tomlinson, B.,Waye, M. M., Chow, A. H., and Chow, M. S. (2004) Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole. Pharmacogenetics 14, 841-850.
91. Yuan, C. S.,Wei, G., Dey, L., Karrison, T., Nahlik, L.,Maleckar, S., Kasza, K., Ang-Lee, M., and Moss, J. (2004) Brief communication: American ginseng reduces warfarin's effect in healthy patients: a randomized, controlled trial. Ann. Intern. Med. 141, 23-27.
92. Butterweck, V. (2003) Mechanism of action of St. John's wort in depression: what is known? CNS Drugs 17, 539-562.
93. Moore, L. B., Goodwin, B., Jones, S. A., Wisely, G. B., Serabjit-Singh, C. J., Willson, T. M., Collins, J. L., and Kliewer, S. A. (2000) St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc. Natl Acad. Sci. USA 97, 7500-7502.
94. Godtel-Armbrust, U., Metzger, A., Kroll, U., Kelber, O., and Wojnowski, L. (2007) Variability in PXR-mediated induction of CYP3A4 by commercial preparations and dry extracts of St. John's wort. Naunyn Schmiedebergs Arch. Pharmacol. 375, 377-382.
95. Mueller, S. C., Uehleke, B., Woehling, H., Petzsch, M., Majcher-Peszynska, J., Hehl, E. M., Sievers, H., Frank, B., Riethling, A. K., and Drewelow, B. (2004) Effect of St. John's wort dose and preparations on the pharmacokinetics of digoxin. Clin. Pharmacol. Ther. 75, 546-557.
96. Mueller, S. C., Majcher-Peszynska, J., Uehleke, B., Klammt, S., Mundkowski, R. G., Miekisch, W., Sievers, H., Bauer, S., Frank, B., Kundt, G., et al. (2006) The extent of induction of CYP3A by St. John's wort varies among products and is linked to hyperforin dose. Eur. J. Clin. Pharmacol. 62, 29-36.
97. Tirona, R. G. and Bailey, D. G. (2006) Herbal product-drug interactions mediated by induction. Br. J. Clin. Pharmacol. 61, 677-681.
98. Zhang, P., Noordine, M. L., Cherbuy, C., Vaugelade, P., Pascussi, J. M., Duee, P. H., and Thomas, M. (2006) Different activation patterns of rat xenobiotic metabolism genes by two constituents of garlic. Carcinogenesis 27, 2090-2095.
99. Fisher, C. D., Augustine, L. M.,Maher, J.M., Nelson, D. M., Slitt, A. L., Klaassen, C. D., Lehman-McKeeman, L.D., and Cherrington, N. J. (2007) Induction of drug-metabolizing enzymes by garlic and allyl sulfide compounds via activation of constitutive androstane receptor and nuclear factor E2-related factor 2. Drug Metab. Dispos. 35, 995-1000.
100. Markowitz, J. S., Donovan, J. L., Lindsay DeVane, C., Sipkes, L., and Chavin, K. D. (2003) Multiple-dose administration of Ginkgo biloba did not affect cytochrome P-450 2D6 or 3A4 activity in normal volunteers. J. Clin. Psychopharmacol. 23, 576-581.
101. Jiang, X., Williams, K. M., Liauw, W. S., Ammit, A. J., Roufogalis, B. D., Duke, C. C., Day, R. O., and McLachlan, A. J. (2004) Effect of St. John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br. J. Clin. Pharmacol. 57, 592-599.
102. Plotnikoff, G. A., McKenna, D., Watanabe, K., and Blumenthal, M. (2004) Ginseng and warfarin interactions. Ann. Intern. Med. 141, 1917-2024.
103. Hardman, J. G., Limbird, L. E., and Gilman, A. G. (2001) Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th edn., McGraw-Hill, New York.
104. Sahi, J., Milad, M. A., Zheng, X., Rose, K. A., Wang, H., Stilgenbauer, L., Gilbert, D., Jolley, S., Stern, R. H., and LeCluyse, E. L. (2003) Avasimibe induces CYP3A4 and multiple drug resistance protein 1 gene expression through activation of the pregnane X receptor. J. Pharmacol. Exp. Ther. 306, 1027-1034.
105. El-Sankary, W., Gibson, G. G., Ayrton, A., and Plant, N. (2001) Use of a reporter gene assay to predict and rank the potency and efficacy of CYP3A4 inducers. Drug Metab. Dispos. 29, 1499-1504.
106. Backman, J. T., Olkkola, K. T., Ojala, M., Laaksovirta, H., and Neuvonen, P. J. (1996) Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. Epilepsia 37, 253-257.
107. Wang, Z., Gorski, J. C., Hamman, M. A., Huang, S. M., Lesko, L. J., and Hall, S. D. (2001) The effects of St. John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin. Pharmacol. Ther. 70, 317-326.
108. Back, D. J., Bates, M., Bowden, A., Breckenridge, A.M., Hall, M. J., Jones, H.,MacIver, M., Orme, M., Perucca, E., Richens, A., et al. (1980) The interaction of phenobarbital and other anticonvulsantswith oral contraceptive steroid therapy. Contraception 22, 495-503.
109. Backman, J. T., Olkkola, K. T., and Neuvonen, P. J. (1996) Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin. Pharmacol. Ther. 59, 7-13.
110. Dingemanse, J., Schaarschmidt, D., and Van Giersbergen, P. L. (2003) Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin. Clin. Pharmacokinet. 42, 293-301.
111. Mouly, S., Lown, K. S., Kornhauser, D., Joseph, J. L., Fiske, W. D., Benedek, I. H., and Watkins, P. B. (2002) Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin. Pharmacol. Ther. 72, 1-9.
112. Rosenfeld, W. E., Doose, D. R., Walker, S. A., and Nayak, R. K. (1997) Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. Epilepsia 38, 317-323.
113. Jones, S. A., Moore, L. B., Shenk, J. L., Wisely, G. B., Hamilton, G. A., McKee, D. D., Tomkinson, N. C., LeCluyse, E. L., Lambert, M. H., Willson, T. M., et al. (2000) The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution. Mol. Endocrinol. 14, 27-39.
114. Prueksaritanont, T., Vega, J. M., Zhao, J., Gagliano, K., Kuznetsova, O., Musser, B., Amin, R. D., Liu, L., Roadcap, B. A., Dilzer, S., et al. (2001) Interactions between simvastatin and troglitazone or pioglitazone in healthy subjects. J. Clin. Pharmacol. 41, 573-581.
115. Goodwin, B., Redinbo, M. R., and Kliewer, S. A. (2002) Regulation of cyp3a gene transcription by the pregnane x receptor. Annu. Rev. Pharmacol. Toxicol. 42, 1-23.
116. Drocourt, L., Pascussi, J. M., Assenat, E., Fabre, J. M., Maurel, P., and Vilarem, M. J. (2001) Calcium channel modulators of the dihydropyridine family are human pregnane X receptor activators and inducers of CYP3A, CYP2B, and CYP2C in human hepatocytes. Drug Metab. Dispos. 29, 1325-1331.
117. Kocarek, T. A., Dahn, M. S., Cai, H., Strom, S. C., and Mercer-Haines, N. A. (2002) Regulation of CYP2B6 and CYP3A expression by hydroxymethylglutaryl coenzyme A inhibitors in primary cultured human hepatocytes. Drug Metab. Dispos. 30, 1400-1405.
118. Sahi, J., Black, C. B., Hamilton, G. A., Zheng, X., Jolley, S., Rose, K. A., Gilbert, D., LeCluyse, E. L., and Sinz, M.W. (2003) Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab. Dispos. 31, 439-446.
119. Kumar, G. N., Rodrigues, A. D., Buko, A. M., and Denissen, J. F. (1996) Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J. Pharmacol. Exp. Ther. 277, 423-431.
120. Tirona, R. G., Leake, B. F.,Wolkoff, A.W., and Kim, R. B. (2003) Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J. Pharmacol. Exp. Ther. 304, 223-228.
121. Niemi, M., Kivisto, K. T., Diczfalusy, U., Bodin, K., Bertilsson, L., Fromm, M. F., and Eichelbaum, M. (2006) Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin. Pharmacogenet. Genomics 16, 565-568.
122. Tirona, R. G. and Kim, R. B. (2005) Nuclear receptors and drug disposition gene regulation. J. Pharm. Sci. 94, 1169-1186.
123. Echchgadda, I., Song, C. S., Roy, A. K., and Chatterjee, B. (2004) Dehydroepiandrosterone sulfotransferase is a target for transcriptional induction by the vitamin D receptor. Mol. Pharmacol. 65, 720-729.
124. Hesse, L.M., Venkatakrishnan, K., Court, M. H., von Moltke, L. L., Duan, S. X., Shader, R. I., and Greenblatt, D. J. (2000) CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab. Dispos. 28, 1176-1183.
125. Faucette, S. R., Hawke, R. L., Lecluyse, E. L., Shord, S. S., Yan, B., Laethem, R. M., and Lindley, C. M. (2000) Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab. Dispos. 28, 1222-1230.
126. Loboz, K. K., Gross, A. S., Williams, K. M., Liauw, W. S., Day, R. O., Blievernicht, J. K., Zanger, U. M., and McLachlan, A. J. (2006) Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. Clin. Pharmacol. Ther. 80, 75-84.
127. Hogeland, G.W., Swindells, S., McNabb, J. C., Kashuba, A. D., Yee, G. C., and Lindley, C. M. (2007) Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects. Clin. Pharmacol. Ther. 81, 69-75.
128. Heimark, L. D., Gibaldi, M., Trager, W. F., O'Reilly, R. A., and Goulart, D. A. (1987) The mechanism of the warfarin-rifampin drug interaction in humans. Clin. Pharmacol. Ther. 42, 388-394.
129. Rengelshausen, J., Banfield, M., Riedel, K. D., Burhenne, J., Weiss, J., Thomsen, T., Walter-Sack, I., Haefeli, W. E., and Mikus, G. (2005) Opposite effects of short-term and long-term St. John's wort intake on voriconazole pharmacokinetics. Clin. Pharmacol. Ther. 78, 25-33.
130. Floyd, M. D., Gervasini, G., Masica, A. L., Mayo, G., George, A. L., Jr., Bhat, K., Kim, R. B., and Wilkinson, G. R. (2003) Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics 13, 595-606.
131. Green, M. D. and Tephly, T. R. (1996) Glucuronidation of amines and hydroxylated xenobiotics and endobiotics catalyzed by expressed human UGT1.4 protein. Drug Metab. Dispos. 24, 356-363.
132. Van Der Lee, M. J., Dawood, L., Ter Hofstede, H. J., De Graaff-Teulen, M. J., Van Ewijk-Beneken Kolmer, E.W., Caliskan-Yassen, N., Koopmans, P. P., and Burger, D. M. (2006) Lopinavir/ritonavir reduces lamotrigine plasma concentrations in healthy subjects. Clin. Pharmacol. Ther. 80, 159-168.
133. Barbier, O., Turgeon, D., Girard, C., Green, M. D., Tephly, T. R., Hum, D. W., and Belanger, A. (2000) 3'-Azido-3'-deoxythymidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7). Drug Metab. Dispos. 28, 497-502.
134. Burger, D. M., Meenhorst, P. L., Koks, C. H., and Beijnen, J. H. (1993) Pharmacokinetic interaction between rifampin and zidovudine. Antimicrob. Agents Chemother. 37, 1426-1431.
135. Gallicano, K. D., Sahai, J., Shukla, V. K., Seguin, I., Pakuts, A., Kwok, D., Foster, B. C., and Cameron, D. W. (1999) Induction of zidovudine glucuronidation and amination pathways by rifampicin in HIV-infected patients. Br. J. Clin. Pharmacol. 48, 168-179.
136. Burk, O., Arnold, K. A., Geick, A., Tegude, H., and Eichelbaum, M. (2005) A role for constitutive androstane receptor in the regulation of human intestinal MDR1 expression. Biol. Chem. 386, 503-513.
137. Greiner, B., Eichelbaum, M., Fritz, P., Kreichgauer, H. P., Von Richter, O., Zundler, J., and Kroemer, H. K. (1999) The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J. Clin. Invest. 104, 147-153.
138. Fromm, M. F., Kauffmann, H. M., Fritz, P., Burk, O., Kroemer, H. K., Warzok, R. W., Eichelbaum, M., Siegmund,W., and Schrenk, D. (2000) The effect of rifampin treatment on intestinal expression of human MRP transporters. Am. J. Pathol., 157, 1575-1580.
139. Kauffmann, H. M., Keppler, D., Gant, T.W., and Schrenk, D. (1998) Induction of hepatic mrp2 (cmrp/cmoat) gene expression in nonhuman primates treated with rifampicin or tamoxifen. Arch. Toxicol. 72, 763-768.
140. Bolt, H. M.,Bolt, M., and Kappus,H. (1977) Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man. Acta Endocrinol. (Copenh.) 85, 189-197.
141. Eich-Hochli, D., Oppliger, R., Golay, K. P., Baumann, P., and Eap, C. B. (2003) Methadone maintenance treatment and St. John's wort-a case report. Pharmacopsychiatry 36, 35-37.
142. Fromm, M. F., Eckhardt, K., Li, S., Schanzle, G., Hofmann, U., Mikus, G., and Eichelbaum, M. (1997) Loss of analgesic effect of morphine due to coadministration of rifampin. Pain 72, 261-267.
143. Bauer, B., Yang, X., Hartz, A. M., Olson, E. R., Zhao, R., Kalvass, J. C., Pollack, G. M., and Miller, D. S. (2006) In vivo activation of human pregnane X receptor tightens the blood-brain barrier to methadone through P-glycoprotein up-regulation. Mol. Pharmacol. 70, 1212-1219.
144. Barone, G. W., Gurley, B. J., Ketel, B. L., Lightfoot, M. L., and Abul-Ezz, S. R. (2000) Drug interaction between St. John's wort and cyclosporine. Ann. Pharmacother. 34, 1013-1016.
145. Breidenbach, T., Hoffmann, M. W., Becker, T., Schlitt, H., and Klempnauer, J. (2000) Drug interaction of St. John's wort with cyclosporine. Lancet 355, 1912.
146. Patsalos, P. N. and Perucca, E. (2003) Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol. 2, 347-356.
147. Back, D. J. (2006) Drug-drug interactions that matter. Top. HIV Med. 14, 88-92.
148. Reilly, P. A., Inaba, T., Kadar, D., and Endrenyi, L. (1978) Enzyme induction following a single dose of amobarbital in dogs. J. Pharmacokinet. Biopharm. 6, 305-313.
149. Bertilsson, L., Hojer, B., Tybring, G., Osterloh, J., and Rane, A. (1980) Autoinduction of carbamazepine metabolism in children examined by a stable isotope technique. Clin. Pharmacol. Ther. 27, 83-88.
150. Tran, J. Q., Kovacs, S. J., McIntosh, T. S., Davis, H. M., and Martin, D. E. (1999) Morning spot and 24-hour urinary 6 beta-hydroxycortisol to cortisol ratios: intraindividual variability and correlation under basal conditions and conditions of CYP 3A4 induction. J. Clin. Pharmacol. 39, 487-494.
151. Wang, H., Huang, H., Li, H., Teotico, D. G., Sinz, M., Baker, S. D., Staudinger, J., Kalpana, G., Redinbo, M. R., and Mani, S. (2007) Activated pregnenolone X-receptor is a target for ketoconazole and its analogs. Clin. Cancer. Res. 13, 2488-2495.
152. Huang, H., Wang, H., Sinz, M., Zoeckler, M., Staudinger, J., Redinbo, M. R., Teotico, D. G., Locker, J., Kalpana, G. V., and Mani, S. (2007) Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole. Oncogene 26, 258-268.
153. Synold, T. W., Dussault, I., and Forman, B. M. (2001) The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat. Med. 7, 584-590.
154. Zhou, C., Poulton, E. J., Grun, F., Bammler, T. K., Blumberg, B., Thummel, K. E., and Eaton, D. L. (2007) The dietary isothiocyanate sulforaphane is an antagonist of the human steroid and xenobiotic nuclear receptor. Mol. Pharmacol. 71, 220-229.
155. Carter, B. A., Prendergast, D. R., Taylor, O. A., Zimmerman, T. L., Furstenberg, R. V., Moore, D. D., and Karpen, S. J. (2007) Stigmasterol, a soy lipid-derived phytosterol, is an antagonist of the bile acid nuclear receptor FXR. Pediatr. Res. 62, 301-306.
156. Shah, S. C., Sharma, R. K., Hemangini, and Chitle, A. R. (1981) Rifampicin induced osteomalacia. Tubercle 62, 207-209.
157. Pascussi, J.M., Robert, A., Nguyen, M.,Walrant-Debray, O., Garabedian, M.,Martin, P., Pineau, T., Saric, J.,Navarro, F., Maurel, P., et al. (2005) Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. J. Clin. Invest. 115, 177-186.
158. Zhou, C., Assem, M., Tay, J. C., Watkins, P. B., Blumberg, B., Schuetz, E. G., and Thummel, K. E. (2006) Steroid and xenobiotic receptor and vitamin D receptor crosstalk mediates CYP24 expression and drug-induced osteomalacia. J. Clin. Invest. 116, 1703-1712.
159. Terzolo, M., Borretta, G., Ali, A., Cesario, F., Magro, G., Boccuzzi, A., Reimondo, G., and Angeli, A. (1995) Misdiagnosis of Cushing's syndrome in a patient receiving rifampicin therapy for tuberculosis. Horm. Metab. Res. 27, 148-150.
160. Zhai, Y., Pai, H. V., Zhou, J., Amico, J. A., Vollmer, R. R., and Xie,W. (2007) Activation of pregnane X receptor disrupts glucocorticoid and mineralocorticoid homeostasis. Mol. Endocrinol. 21, 138-147.
161. Eiris-Punal, J., Del Rio-Garma, M., Del Rio-Garma, M. C., Lojo-Rocamonde, S., Novo-Rodriguez, I., and Castro-Gago, M. (1999) Long-term treatment of children with epilepsy with valproate or carbamazepine may cause subclinical hypothyroidism. Epilepsia 40, 1761-1766.
162. Kodama, S., Tanaka, K., Konishi, H.,Momota, K., Nakasako, H., Nakayama, S., Yagi, J., and Koderazawa, K. (1989) Supplementary thyroxine therapy in patients with hypothyroidism induced by long-term anticonvulsant therapy. Acta Paediatr. Jpn. 31, 555-562.
163. Takasu, N., Kinjou, Y., Kouki, T., Takara, M., Ohshiro, Y., and Komiya, I. (2006) Rifampin-induced hypothyroidism. J. Endocrinol. Invest. 29, 645-649.
164. Kim, D. L., Song, K. H., Lee, J. H., Lee, K. Y., and Kim, S. K. (2007) Rifampin-induced hypothyroidism without underlying thyroid disease. Thyroid 17, 793-795.
165. Qatanani, M., Zhang, J., and Moore, D. D. (2005) Role of the constitutive androstane receptor in xenobiotic-induced thyroid hormone metabolism. Endocrinology 146, 995-1002.
166. Wong, H., Lehman-McKeeman, L. D., Grubb, M. F., Grossman, S. J., Bhaskaran, V. M., Solon, E. G., Shen, H. S., Gerson, R. J., Car, B. D., Zhao, B., et al. (2005) Increased hepatobiliary clearance of unconjugated thyroxine determines DMP 904-induced alterations in thyroid hormone homeostasis in rats. Toxicol. Sci. 84, 232-242.
167. Vourvahis, M. and Kashuba, A. D. (2007) Mechanisms of pharmacokinetic and pharmacodynamic drug interactions associated with ritonavir-enhanced tipranavir. Pharmacotherapy 27, 888-909.
168. Wipf, P., Gong, H., Janjic, J.M., Li, S., Day, B.W., and Xie,W. (2007) New opportunities for pregnane X receptor (PXR) targeting in drug development. Lessons from enantio- and species-specific PXR ligands identified from a discovery library of amino acid analogues. Mini. Rev. Med. Chem. 7, 617-625.